Similar treatment response to peginterferon and ribavirin in asian and caucasian patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1110-1115

  Vutien, Philip ^a,b   Nguyen, Nghia H ^a,b   Trinh, Huy N ^b,c   Li, Jiayi ^d   Garcia, Ruel T ^b,c   Garcia, Gabriel ^a   Nguyen, Khanh K ^c   Nguyen, Huy A ^c   Levitt, Brian S ^c   Keeffe, Emmet B ^a   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Pacific Health Foundation   (United States)

^c San Jose Gastroenterology   (United States)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; ARTICLE; ASIAN; CAUCASIAN; COUGHING; DEPRESSION; DRUG DOSE REDUCTION; DYSPNEA; ETHNICITY; FATIGUE; FEVER; HEARING LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; VISUAL IMPAIRMENT;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; PROBABILITY; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77951976635     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.635     Document Type: Article

References (37)

1. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-355
2. Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol 2008; 103: 131-137
3. Fried MW, Shiff man ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
5. Hepburn MJ, Hepburn LM, Cantu NS et al. Diff erences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-168
6. Jeff ers LJ, Cassidy W, Howell CD et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708 (Pubitemid 38702672)
7. McHutchison JG, Poynard T, Pianko S et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 1317-1323
8. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271
9. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial diff erences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-793
10. Rodriguez-Torres M, Jeff ers LJ, Sheikh MY et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-267
11. Sterling RK, Stravitz RT, Luketic VA et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 469-473
12. Dev AT, McCaw R, Sundararajan V et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 1259-1265
13. Furusyo N, Kajiwara E, Takahashi K et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their eff ectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008; 23: 1094-1104
14. Kuboki M, Iino S, Okuno T et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22: 645-652
15. Lee H, Choi MS, Paik SW et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol 2006; 12: 31-40.
16. Lee HJ, Eun JR, Choi JW et al. Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C. Korean J Hepatol 2008; 14: 46-57.
17. Liu CH, Liu CJ, Lin CL et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269
18. Missiha S, Heathcote J, Arenovich T et al. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-2188
19. Shirakawa H, Matsumoto A, Joshita S et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-1760
20. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unifi ed system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973
21. Yan KK, Guirgis M, Dinh T et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14: 3416-3420
22. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893
23. Yu ML, Dai CY, Lin ZY et al. A randomized trial of 24-vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006; 26: 73-81.
24. Ioannou GN, Dominitz JA, Weiss NS et al. Racial diff erences in the relationship between hepatitis C infection and iron stores. Hepatology 2003; 37: 795-801.
25. Kimball P, Elswick RK, Shiff man M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001; 65: 510-516
26. Yee LJ, Im K, Wahed AS et al. Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother 2009; 53: 615-621
27. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91: 8239-8243
28. Mizokami M, Gojobori T, Ohba K et al. Hepatitis C virus types 7, 8 and 9 should be classifi ed as type 6 subtypes. J Hepatol 1996; 24: 622-624
29. Nguyen MH, Keeff e EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3: S97-101.
30. Stuyver L, Wyseur A, van Arnhem W et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259-2266
31. Fung J, Lai CL, Hung I et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 808-812
32. Hui C-K, Yuen M-F, Sablon E et al. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 1071-1074 (Pubitemid 36399349)
33. Yuen M-F, Lai C-L. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006; 49: 96-98
34. Freshwater DA, O'Donnell K, Mutimer DJ. Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. J Viral Hepat 2008; 15: 115-119
35. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-345
36. Cheng JT, Hsien C, Sun HE et al. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 2737-2743
37. Fancher TL, Ton H, Le Meyer O et al. Discussing depression with Vietnamese American patients. J Immigr Minor Health 2009; e-pub ahead of print.